{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:58:20Z","timestamp":1787003900455,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,2,23]],"date-time":"2010-02-23T00:00:00Z","timestamp":1266883200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1038\/tpj.2010.10","type":"journal-article","created":{"date-parts":[[2010,2,23]],"date-time":"2010-02-23T06:04:19Z","timestamp":1266905059000},"page":"61-71","source":"Crossref","is-referenced-by-count":95,"title":["Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"B","family":"Glimelius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Garmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L A","family":"Fredriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kohnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Bystr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"S\u00f8rbye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Wadelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,2,23]]},"reference":[{"key":"BFtpj201010_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2002.20.1.7","volume":"20","author":"MJ Ratain","year":"2002","unstructured":"Ratain MJ . Irinotecan dosing: does the CPT in CPT-11 stand for \u201cCan\u2019t Predict Toxicity\u201d? J Clin Oncol 2002; 20: 7\u20138.","journal-title":"J Clin Oncol"},{"key":"BFtpj201010_CR2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2165\/00002018-200528050-00005","volume":"28","author":"B Glimelius","year":"2005","unstructured":"Glimelius B . Benefit-risk assessment of irinotecan in advanced colorectal cancer. Drug Saf 2005; 28: 417\u2013433.","journal-title":"Drug Saf"},{"key":"BFtpj201010_CR3","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0009-9236(99)70078-0","volume":"65","author":"L Iyer","year":"1999","unstructured":"Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999; 65: 576\u2013582.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201010_CR4","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1023\/A:1008261821434","volume":"8","author":"E Wasserman","year":"1997","unstructured":"Wasserman E, Myara A, Lokiec F, Goldwasser F, Trivin F, Mahjoubi M et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997; 8: 1049\u20131051.","journal-title":"Ann Oncol"},{"key":"BFtpj201010_CR5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.clpt.2004.01.011","volume":"75","author":"F Innocenti","year":"2004","unstructured":"Innocenti F, Ratain MJ . \u201cIrinogenetics\u201d and UGT1A: from genotypes to haplotypes. Clin Pharmacol Ther 2004; 75: 495\u2013500.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201010_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/FTD.0b013e318068623b","volume":"29","author":"TW Kim","year":"2007","unstructured":"Kim TW, Innocenti F . Insights, challenges, and future directions in irinogenetics. Ther Drug Monit 2007; 29: 265\u2013270.","journal-title":"Ther Drug Monit"},{"key":"BFtpj201010_CR7","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ctrv.2008.05.002","volume":"34","author":"D Kweekel","year":"2008","unstructured":"Kweekel D, Guchelaar HJ, Gelderblom H . Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev 2008; 34: 656\u2013669.","journal-title":"Cancer Treat Rev"},{"key":"BFtpj201010_CR8","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0140-6736(96)91273-8","volume":"347","author":"G Monaghan","year":"1996","unstructured":"Monaghan G, Ryan M, Seddon R, Hume R, Burchell B . Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996; 347: 578\u2013581.","journal-title":"Lancet"},{"key":"BFtpj201010_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/sj.tpj.6500072","volume":"2","author":"L Iyer","year":"2002","unstructured":"Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2: 43\u201347.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201010_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.clpt.2004.01.010","volume":"75","author":"K Sai","year":"2004","unstructured":"Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004; 75: 501\u2013515.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201010_CR11","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1177\/0091270004267159","volume":"44","author":"L Paoluzzi","year":"2004","unstructured":"Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 2004; 44: 854\u2013860.","journal-title":"J Clin Pharmacol"},{"key":"BFtpj201010_CR12","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1200\/JCO.2008.19.0314","volume":"27","author":"E Cecchin","year":"2009","unstructured":"Cecchin E, Innocenti F, D\u2019Andrea M, Corona G, De Mattia E, Biason P et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 2009; 27: 2457\u20132465.","journal-title":"J Clin Oncol"},{"key":"BFtpj201010_CR13","first-page":"6921","volume":"60","author":"Y Ando","year":"2000","unstructured":"Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921\u20136926.","journal-title":"Cancer Res"},{"key":"BFtpj201010_CR14","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/cncr.23777","volume":"113","author":"JF Deeken","year":"2008","unstructured":"Deeken JF, Slack R, Marshall JL . Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question. Cancer 2008; 113: 1502\u20131510.","journal-title":"Cancer"},{"key":"BFtpj201010_CR15","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","volume":"22","author":"F Innocenti","year":"2004","unstructured":"Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382\u20131388.","journal-title":"J Clin Oncol"},{"key":"BFtpj201010_CR16","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/sj.tpj.6500463","volume":"8","author":"A Ruzzo","year":"2008","unstructured":"Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, Bisonni R et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 2008; 8: 278\u2013288.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201010_CR17","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1002\/cncr.23370","volume":"112","author":"CY Liu","year":"2008","unstructured":"Liu CY, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 2008; 112: 1932\u20131940.","journal-title":"Cancer"},{"key":"BFtpj201010_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/sj.bjc.6604461","volume":"99","author":"DM Kweekel","year":"2008","unstructured":"Kweekel DM, Gelderblom H, Van der Straaten T, Antonini NF, Punt CJ, Guchelaar HJ . UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer 2008; 99: 275\u2013282.","journal-title":"Br J Cancer"},{"key":"BFtpj201010_CR19","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2005.05.5400","volume":"24","author":"G Toffoli","year":"2006","unstructured":"Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D\u2019Andrea M et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24: 3061\u20133068.","journal-title":"J Clin Oncol"},{"key":"BFtpj201010_CR20","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1158\/1078-0432.CCR-03-0548","volume":"10","author":"E Rouits","year":"2004","unstructured":"Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E . Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004; 10: 5151\u20135159.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201010_CR21","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1158\/1078-0432.CCR-06-2290","volume":"13","author":"JF Cote","year":"2007","unstructured":"Cote JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007; 13: 3269\u20133275.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201010_CR22","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/jnci\/djm115","volume":"99","author":"JM Hoskins","year":"2007","unstructured":"Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL . UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007; 99: 1290\u20131295.","journal-title":"J Natl Cancer Inst"},{"key":"BFtpj201010_CR23","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/sj.bjc.6602042","volume":"91","author":"E Marcuello","year":"2004","unstructured":"Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M . UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004; 91: 678\u2013682.","journal-title":"Br J Cancer"},{"key":"BFtpj201010_CR24","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/cncr.21722","volume":"106","author":"C Massacesi","year":"2006","unstructured":"Massacesi C, Terrazzino S, Marcucci F, Rocchi MB, Lippe P, Bisonni R et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 2006; 106: 1007\u20131016.","journal-title":"Cancer"},{"key":"BFtpj201010_CR25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3816\/CCC.2007.n.026","volume":"6","author":"MG Fakih","year":"2007","unstructured":"Fakih MG, Ross ME, Starostik P . Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7\/7 in patients experiencing severe irinotecan-induced toxicities. Clin Colorectal Cancer 2007; 6: 583\u2013587.","journal-title":"Clin Colorectal Cancer"},{"key":"BFtpj201010_CR26","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1158\/1078-0432.1226.11.3","volume":"11","author":"LE Carlini","year":"2005","unstructured":"Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine\/irinotecan. Clin Cancer Res 2005; 11: 1226\u20131236.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201010_CR27","first-page":"497","volume":"16","author":"RZ Romero","year":"2006","unstructured":"Romero RZ, Morales R, Garcia F, Huarriz M, Bandres E, De la Haba J et al. Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients. Oncol Rep 2006; 16: 497\u2013503.","journal-title":"Oncol Rep"},{"key":"BFtpj201010_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10637-005-4022-6","volume":"23","author":"M Ando","year":"2005","unstructured":"Ando M, Hasegawa Y, Ando Y . Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan. Invest New Drugs 2005; 23: 539\u2013545.","journal-title":"Invest New Drugs"},{"key":"BFtpj201010_CR29","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1200\/JCO.2005.03.0239","volume":"24","author":"JY Han","year":"2006","unstructured":"Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006; 24: 2237\u20132244.","journal-title":"J Clin Oncol"},{"key":"BFtpj201010_CR30","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1124\/dmd.108.024208","volume":"37","author":"Y Saito","year":"2009","unstructured":"Saito Y, Sai K, Maekawa K, Kaniwa N, Shirao K, Hamaguchi T et al. Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese. Drug Metab Dispos 2009; 37: 272\u2013276.","journal-title":"Drug Metab Dispos"},{"key":"BFtpj201010_CR31","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1200\/JCO.2008.20.6300","volume":"27","author":"F Innocenti","year":"2009","unstructured":"Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, Relling M et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009; 27: 2604\u20132614.","journal-title":"J Clin Oncol"},{"key":"BFtpj201010_CR32","first-page":"3246","volume":"9","author":"RH Mathijssen","year":"2003","unstructured":"Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003; 9: 3246\u20133253.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201010_CR33","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/00008571-200312000-00005","volume":"13","author":"K Sai","year":"2003","unstructured":"Sai K, Kaniwa N, Itoda M, Saito Y, Hasegawa R, Komamura K et al. Haplotype analysis of ABCB1\/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 2003; 13: 741\u2013757.","journal-title":"Pharmacogenetics"},{"key":"BFtpj201010_CR34","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/cncr.22760","volume":"110","author":"JY Han","year":"2007","unstructured":"Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007; 110: 138\u2013147.","journal-title":"Cancer"},{"key":"BFtpj201010_CR35","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2217\/14622416.6.7.673","volume":"6","author":"K Robien","year":"2005","unstructured":"Robien K, Boynton A, Ulrich CM . Pharmacogenetics of folate-related drug targets in cancer treatment. Pharmacogenomics 2005; 6: 673\u2013689.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201010_CR36","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3109\/07357909909032859","volume":"17","author":"L Iyer","year":"1999","unstructured":"Iyer L, Ratain MJ . 5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Invest 1999; 17: 494\u2013506.","journal-title":"Cancer Invest"},{"key":"BFtpj201010_CR37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1247\/csf.20.191","volume":"20","author":"N Horie","year":"1995","unstructured":"Horie N, Aiba H, Oguro K, Hojo H, Takeishi K . Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5\u2032-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20: 191\u2013197.","journal-title":"Cell Struct Funct"},{"key":"BFtpj201010_CR38","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2217\/14622416.9.8.1079","volume":"9","author":"S Funke","year":"2008","unstructured":"Funke S, Brenner H, Chang-Claude J . Pharmacogenetics in colorectal cancer: a systematic review. Pharmacogenomics 2008; 9: 1079\u20131099.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201010_CR39","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1200\/JCO.2005.06.219","volume":"23","author":"A Jakobsen","year":"2005","unstructured":"Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J . Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005; 23: 1365\u20131369.","journal-title":"J Clin Oncol"},{"key":"BFtpj201010_CR40","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1093\/annonc\/mdf324","volume":"13","author":"B Glimelius","year":"2002","unstructured":"Glimelius B, Ristamaki R, Kjaer M, Pfeiffer P, Skovsgaard T, Tveit KM et al. Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol 2002; 13: 1868\u20131873.","journal-title":"Ann Oncol"},{"key":"BFtpj201010_CR41","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/annonc\/mdm588","volume":"19","author":"B Glimelius","year":"2008","unstructured":"Glimelius B, Sorbye H, Balteskard L, Bystrom P, Pfeiffer P, Tveit KM et al. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus\/infused de Gramont schedule (LV5FU2) in patients with metastatic colorectal cancer. Ann Oncol 2008; 19: 909\u2013914.","journal-title":"Ann Oncol"},{"key":"BFtpj201010_CR42","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205\u2013216.","journal-title":"J Natl Cancer Inst"},{"key":"BFtpj201010_CR43","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0361-090X(03)00103-X","volume":"27","author":"W Cao","year":"2003","unstructured":"Cao W, Hashibe M, Rao JY, Morgenstern H, Zhang ZF . Comparison of methods for DNA extraction from paraffin-embedded tissues and buccal cells. Cancer Detect Prev 2003; 27: 397\u2013404.","journal-title":"Cancer Detect Prev"},{"key":"BFtpj201010_CR44","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S0009-9120(03)00092-4","volume":"36","author":"K Saito","year":"2003","unstructured":"Saito K, Miyake S, Moriya H, Yamazaki M, Itoh F, Imai K et al. Detection of the four sequence variations of MDR1 gene using TaqMan MGB probe based real-time PCR and haplotype analysis in healthy Japanese subjects. Clin Biochem 2003; 36: 511\u2013518.","journal-title":"Clin Biochem"},{"key":"BFtpj201010_CR45","doi-asserted-by":"publisher","first-page":"7592","DOI":"10.1158\/1078-0432.CCR-04-1057","volume":"10","author":"K Robien","year":"2004","unstructured":"Robien K, Ulrich CM, Bigler J, Yasui Y, Gooley T, Bruemmer B et al. Methylenetetrahydrofolate reductase genotype affects risk of relapse after hematopoietic cell transplantation for chronic myelogenous leukemia. Clin Cancer Res 2004; 10: 7592\u20137598.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201010_CR46","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/10618600.1996.10474713","volume":"5","author":"R Ihaka","year":"1996","unstructured":"Ihaka R, Gentleman R . R: A language for data analysis and graphics. J Comput Graph Stat 1996; 5: 299\u2013314.","journal-title":"J Comput Graph Stat"},{"key":"BFtpj201010_CR47","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1086\/379378","volume":"73","author":"M Stephens","year":"2003","unstructured":"Stephens M, Donnelly P . A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73: 1162\u20131169.","journal-title":"Am J Hum Genet"},{"key":"BFtpj201010_CR48","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/sj.bjc.6602462","volume":"92","author":"E Van Cutsem","year":"2005","unstructured":"Van Cutsem E, Dirix L, Van Laethem JL, Van Belle S, Borner M, Gonzalez Baron M et al. Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. Br J Cancer 2005; 92: 1055\u20131062.","journal-title":"Br J Cancer"},{"key":"BFtpj201010_CR49","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00228-002-0490-1","volume":"58","author":"M Holthe","year":"2002","unstructured":"Holthe M, Klepstad P, Zahlsen K, Borchgrevink PC, Hagen L, Dale O et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 2002; 58: 353\u2013356.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtpj201010_CR50","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00228-006-0166-3","volume":"62","author":"J Mercke Odeberg","year":"2006","unstructured":"Mercke Odeberg J, Andrade J, Holmberg K, Hoglund P, Malmqvist U, Odeberg J . UGT1A polymorphisms in a Swedish cohort and a human diversity panel, and the relation to bilirubin plasma levels in males and females. Eur J Clin Pharmacol 2006; 62: 829\u2013837.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtpj201010_CR51","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1093\/annonc\/mdm267","volume":"18","author":"H Sorbye","year":"2007","unstructured":"Sorbye H, Kohne CH, Sargent DJ, Glimelius B . Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. Ann Oncol 2007; 18: 1666\u20131672.","journal-title":"Ann Oncol"},{"key":"BFtpj201010_CR52","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa0809329","volume":"360","author":"TE Klein","year":"2009","unstructured":"International warfarin pharmacogenetics consortium. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753\u2013764.","journal-title":"N Engl J Med"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/tpj201010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/tpj201010","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/tpj201010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T14:34:01Z","timestamp":1739889241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,23]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["BFtpj201010"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2010.10","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,23]]}}}